Type of estrogen receptor determines response to antiestrogen therapy

Cancer Research

Volumn 56, Issue 17, 1996, Pages 3883-3885

  Villa, Erica ^a   Dugani, Aisha ^a   Fantoni, Emanuela ^a   Camellini, Lorenzo ^a   Buttafoco, Paola ^a   Grottola, Antonella ^a   Pompei, Guglielmo ^b   De Santis, Mario ^c   Ferrari, Alberto ^a   Manenti, Federico ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Regione Piemonte USL 49   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; MEGESTROL; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MEGESTROL; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 9444267705     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Group d'etude et de traitement du carcinome hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma N. Engl. J Med , 332: 1256-1261, 1995
2. Livraghi, T , Bolondi, L , Lazzaroni, S., Marin, G., Morabito, A., Rapaccini, G. L., and Salmi, A. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma: a study on 207 patients. Cancer (Phila), 68: 926-929, 1992.
3. Porter, L. E., Elm, M. S., Van Thiel, D. H , Dugas, M. C , and Eagon, P. K. Characterization and quantitation of human hepatic estrogen receptors. Gastroenterology, 84, 704-712, 1983.
4. Rossini, G. P., Baldini, G. M , Villa, E., and Manenti, F. Characterization of estrogen receptors from human liver. Gassroenterology, 96, 1102-1109, 1989.
5. Neuberger, J., Portmann, B., Nunnerly, H. B., Laws, J. W , Davis, M , and Williams, R. Oral contraceptive-associated liver tumours: occurrence of malignancy and difficulties in diagnosis. Lancet, I: 273-275, 1980.
6. Mariani, A. F., Livingstone, A. S., Pereira, R. V., Jr, Van Zuiden, P E , and Schiff, E. R Progressive enlargement of an hepatic cell adenoma. Gastroenterology, 77; 1319-1325, 1975.
7. Farinati, F., Salvagnini, M , De Maria, N., Fornasiero, A., Chiaramonte, M., Rossaro, L., Naccarato, R. Unresectable hepatocellular carcinoma. A prospective controlled trial with tamoxifen. J. Hepatol , 11: 297-301, 1990.
8. Martinez-Cereso, F. J., Tomas, A., Enriquez, J., Donoso, L., Balanzo, J , and Guarner, C Tamoxifen improves survival in patients with advanced hepatocellular carcinoma. J. Hepatol., 20: 702-706, 1994.
9. Castells, A., Bruix, J., Brum, C., Ayuso, C., Roca, M., Boix, L , Vilana, R., and Rodes, J. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind trial in 120 patients. Gastroenterology, 109. 917-922, 1995
10. Villa, E , Camellini, L , Dugani, A , Zucchi, F , Losi, L., Buttafoco, P , Grottola, A., Menghi, A L , and Manenti, F. Variant estrogen receptors mRNA species detected in human primary hepatocellular carcinoma. Cancer Res , 55: 498-500, 1995.
11. Villa, E., Camellini, L., Dugani, A., Buttafoco, P., Grottola, A., and Manenti F. Variant liver estrogen receptors and response to tamoxifen. Gastroenterology, 111: 271-272, 1996
12. Collins, M., Loeffler, R. K , and Tivey, H. Observation on growth rates in human tumours. Am. J. Roentgenol., 76 988-1000, 1956.
13. Bolondi, L., Benzi, G., Santi, V , Gaiani, S., Li Bassi, S., Zironi, G., Mazziotti, A , Sama, C., Grigioni, W., and Gozzetti, G. Relationship between α-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a Western population. Ital. J. Gastroenterol, 22 190-194, 1990
14. Sheu, J. C., Sung, J. L , Chen, D S., Yang, P. M , Lai, M. Y., Lee, C. S., Hsu, H. C., and Sung, J. L. Growth rate of asymptomatic hepatocellular carcinoma and its implications. Gastroenterology, 89: 259-266, 1985.
15. Fuqua, S. A. W., Fitzgerald, S. D., Allred, D C , Elledge, R. M., Nawaz, Z , McDonnell, D. P., O'Malley, B. W , Green, G. L , and McGuire, W. L. Inhibition of estrogen receptor action by naturally occurring variant in human breast tumors. Cancer Res., 52: 483-486, 1992.
16. O'Brian, C. A , Word, N. E., and Anderson, B. W. Role of specific interactions between protein kinase C and triphenyletliylenes in inhibition of the enzyme. J Natl. Cancer Inst., 20: 1628-1633, 1988.
17. Matsuda, S , Kadowaki, Y., and Ichino, M 17β estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc. Natl. Acad. Sci. USA, 90: 10803-10806, 1984.
18. Pollack, M. N., Huynh, H. T , and Lefebvre, S. P. Tamoxifen reduces serum insulin growth factor I. Breast Cancer Res. Treat., 22: 91-100, 1992
19. Friedman, M., Demanes, D. J., Hoffman, P. G Hepatomas: hormone receptors and therapy. Am. J. Med., 73: 362-366, 1982.
20. Camellini, L., Grottola, A., Buttafoco, P , Merighi, A. L., Manenti, F., and Villa, E. Variant liver estrogen receptor (ER) occur in cirrhotics with liver cell dysplasia. Hepatology, 22: 190A, 1995.